Subscribe to RSS
DOI: 10.4103/1947-489X.210551
Metformin, the remarkable and unique antidiabetic agent
In the current issue of this Journal, Fiad and colleagues thoughtfully reviewed in detail the role of metformin in current clinical practice and highlighted the additional effects of metformin independent of the glycemic action of the drug. The review is comprehensive, up to date and is extensively supported by the literature. Metformin remains the first drug of choice in patients diagnosed with type 2 diabetes. Its vascular protection actions are particularly interesting though not yet fully understood. Its antineoplastic actions are very exciting. The authors clarify the issues of gastrointestinal side effects and renal limitations of its use and give practical ways of minimizing the potential loss of benefit to all treated patients.
Publication History
Received: 16 December 2012
Accepted: 16 December 2012
Article published online:
07 July 2022
© 2013. The Libyan Authority of Scientific Research and Technologyand the Libyan Biotechnology Research Center. All rights reserved. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License,permitting copying and reproductionso long as the original work is given appropriate credit. Contents may not be used for commercial purposes, oradapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India